Yoshida T, Shimizu K, Hayakawa T, Mogami H, Sakamoto Y, Egawa T
No Shinkei Geka. 1987 Mar;15(3):261-7.
A calmodulin inhibitor, trifluoperazine, was found to enhance the cytotoxic action of ACNU in C6, especially in ACNU-resistant (C6/ACNU) glioma cells in vitro. In order to clarify the efficacy of trifluoperazine in vivo, 1 X 10(7) C6 or C6/ACNU cells were percutaneously implanted into the cisterna magna of Wistar rats to produce meningeal gliomatosis (MG) models as a chemosensitivity assay system. MG rats were treated with ACNU and trifluoperazine according to a variety of schedules. Trifluoperazine in doses of 250 to 500 micrograms/kg intrathecally (it) administered with 1 mg/kg ACNU 1 day after the tumor inoculation significantly increased the life span of the C6/ACNU bearing (C6/ACNU MG) rats. At doses of 250 and 500 micrograms/kg of trifluoperazine in the C6/ACNU MG rats, values of increased life span of 22 and 30% were obtained with a 1 mg/kg dose of ACNU, respectively. These values were statistically significant compared with that obtained in the C6/ACNU MG rats treated with ACNU alone at 1 mg/kg. It might be concluded that the combination chemotherapy with ACNU and such a calmodulin inhibitor as trifluoperazine could overcome ACNU resistance in malignant brain tumors.
人们发现,一种钙调蛋白抑制剂三氟拉嗪可增强嘧啶亚硝脲(ACNU)对C6细胞的细胞毒性作用,在体外对耐ACNU的(C6/ACNU)胶质瘤细胞尤其如此。为了阐明三氟拉嗪在体内的疗效,将1×10⁷个C6或C6/ACNU细胞经皮植入Wistar大鼠的脑池,以建立脑膜胶质瘤病(MG)模型作为化学敏感性测定系统。MG大鼠按照多种方案接受ACNU和三氟拉嗪治疗。在肿瘤接种后1天,鞘内(it)给予250至500微克/千克剂量的三氟拉嗪并联合1毫克/千克的ACNU,可显著延长携带C6/ACNU的(C6/ACNU MG)大鼠的寿命。在C6/ACNU MG大鼠中,当三氟拉嗪剂量为250和500微克/千克时,给予1毫克/千克剂量的ACNU,寿命延长值分别为22%和30%。与仅接受1毫克/千克ACNU治疗的C6/ACNU MG大鼠相比,这些值具有统计学意义。可以得出结论,ACNU与三氟拉嗪这种钙调蛋白抑制剂联合化疗可克服恶性脑肿瘤中的ACNU耐药性。